Literature DB >> 26490048

Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.

Cigdem Ozkan1, Mujde Akturk, Alev Eroglu Altinova, Ethem Turgay Cerit, Ozlem Gulbahar, Mehmet Muhittin Yalcin, Nuri Cakir, Fusun Balos Toruner.   

Abstract

The cardiovascular effects of short-term overt hypothyroidism are not well known. We investigated proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and the ankle brachial index (ABI) in thyroid cancer patients with short-term overt hypothyroidism due to thyroid hormone withdrawal (THW). Twenty-one patients requiring radioactive iodine (RAI) ablation or scanning and 36 healthy control subjects were enrolled. Patients were evaluated in the subclinical thyrotoxic phase when they were on suppressive levothyroxine therapy and in the overt hypothyroid phase due to THW for four weeks. PCSK9, sLOX-1, lipids and ABI were measured in the patient and control groups. Total cholesterol, LDL cholesterol, triglycerides and Apo B levels were increased in short overt hypothyroidism compared with the control group (p<0.001). PCSK9 levels increased before THW and after THW in the patients compared to control group (p<0.001, p=0.004, respectively). sLOX-1 levels were not different between patients with short term overt hypothyroidism and control group (p=0.27). ABI was found to be significantly decreased in patients with thyroid cancer before and after THW compared to control group (p=0.04, p=0.002 respectively). PCSK9 levels were correlated negatively with ABI (r=-0.38, p=0.004). In conclusion; our study demonstrated that patients with differentiated thyroid cancer both before and after THW which is a short term overt hypothyroid phase, had increased PCSK9 levels and decreased ABI. Short term overt hypothyroidism also leads to increased HDL, LDL, total cholesterol, Apo A and Apo B levels.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26490048     DOI: 10.1507/endocrj.EJ15-0308

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

Review 1.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

Review 2.  PCSK9 targets important for lipid metabolism.

Authors:  Rainer Schulz; Klaus-Dieter Schlüter
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

Review 3.  Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?

Authors:  Julita Anna Krahel; Anna Baran; Tomasz W Kamiński; Iwona Flisiak
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

4.  The Relationship of Circulating Proprotein Convertase Subtilisin/Kexin Type 9 With TSH and Lipid Profile in Newly Diagnosed Patients With Subclinical and Overt Hypothyroidism.

Authors:  Noha Adly Sadik; Laila Ahmed Rashed; Shereen Sadik El-Sawy
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2022-04-21

Review 5.  The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus.

Authors:  Aleksandra Frątczak; Karina Polak; Michał Szczepanek; Anna Lis-Święty
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664

6.  Pro-protein convertase subtilisin/kexin type 9 promotes intestinal tumor development by activating Janus kinase 2/signal transducer and activator of transcription 3/SOCS3 signaling in ApcMin/+ mice.

Authors:  Kai Yang; Jie Zhu; Huan-Hua Luo; Shu-Wen Yu; Lu Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.